Early trial tests new drug combo for Tough-to-Treat cancers
NCT ID NCT05661201
Summary
This early-stage study is testing the safety and finding the right dose of a new drug combination (NEROFE plus doxorubicin) for people with advanced solid tumors that have specific genetic markers (KRAS mutation and ST2-positive). It will enroll 24 participants who have run out of standard treatment options. The main goal is to see how well patients tolerate the treatment and to measure how the drugs behave in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Georgetown Lombardi Comprehensive Cancer Center
RECRUITINGWashington D.C., District of Columbia, 20007, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.